Meeting Banner
Abstract #0367

Hyperpolarized 13C-Pyruvate MRSI in Prediction of Response to Tyrosine Kinase Inhibition Therapy in Gastric Cancer

Shadi A Esfahani 1, Cody Callahan2, Nicholas M Rotile1, Peter D Caravan 1, Aaron K Grant 2, and Yi-Fen Yen1
1Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, United States, 2Department of Radiology, Beth Israel Deaconess Medical Center, Boston, MA, United States

Personalized treatment of gastric cancer remains a major challenge mainly due to lack of an optimal imaging method for detection of early response to treatment. We evaluated the role of Hyperpolarized [1-13C] Pyruvate Magnetic Resonance Spectroscopic Imaging (HP-13C MRSI) for quantitative measurement of early changes in glycolytic metabolism of gastric cancer models upon initiation of afatinib, a pan-receptor tyrosine kinase inhibitor. We showed that HP-13C MRSI is more sensitive for detection of early metabolic changes in gastric cancer after starting treatment with afatinib compared to 18F-FDG PET/MRI, and therefore can be used for early prediction of response to targeted therapies.

This abstract and the presentation materials are available to members only; a login is required.

Join Here